Aratana Therapeutics (PETX) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Aratana Therapeutics, Inc.  (PETX)
 

Aratana Therapeutics Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PETX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 82.04 % 3.86 % 1.96 % 4.17 %
Q / Q Revenue Growth (Q1 MRQ) 50.02 % -3.81 % -3.24 % -6.63 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 49.99 % 5.41 % 3.86 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) 9.37 % 0.89 % 0.42 % 1.1 %
Revenue 5 Year Average Growth 210.35 % 13.18 % 9.12 % 9.52 %


PETX's Growth Comparisons in I. Quarter 2019




Aratana Therapeutics showed respectable 82.04% year on year rise of Revenue in the first quarter 2019, comparing favorably to the 3.86% growth in the Major Pharmaceutical Preparations industry, and 1.96% growth in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the Major Pharmaceutical Preparations industry, Aratana Therapeutics, Inc. reported above average market Sales growth.

Top-line grew by 50.02% from the fourth quarter. Average yearly sales growth for Aratana Therapeutics is 210.35%, while S & P 500's average annual sales increase is 9.52% over the five years, including only Businesses with the first quarter 2019 Results.


Growth Rates of PETX's Income in the first quarter 2019


PETX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) - 18.68 % 64.87 % -10.92 %
Sequential Operating Income Change (Q1 MRQ) - 1817.34 % - 5.3 %
Y / Y Operating Income Growth (Q1 TTM) - 71.18 % -36.3 % -9.58 %
Sequential Operating Income Growth (Q1 TTM) - 3.95 % 27.5 % -2.65 %
Operating Income 5 Year Avg. Change - 2.86 % 2.86 % 11.15 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - 13.92 % 7.15 % -2.54 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - - 127.59 % 7.14 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - 194.03 % 134.15 % 21.95 %
Sequential Income from Cont. Ops. Change (Q1 TTM) - 3.99 % 3.04 % -1.19 %
Income from Cont. Ops. 5 Year Avg. Change - 11.4 % 8.98 % 5.28 %

PETX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - 45.3 % 22.6 % 0.3 %
Q / Q Net Income Growth (Q1 MRQ) - - 213.02 % 10.4 %
Y / Y Net Income Change (Q1 TTM) - 241.12 % 143.59 % 25.14 %
Sequential Net Income Change (Q1 TTM) - 14.51 % 7.11 % -1.04 %
Net Income 5 Year Avg. Growth - 0.15 % 2.63 % 8.91 %

PETX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - 26.23 % 7.15 % -2.54 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - - 127.59 % 7.14 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - -3.59 %
EPS from Cont. Ops. 5 Year Avg. Growth - -1.95 % 8.98 % 5.28 %



PETX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - 60.99 % 22.6 % 5.28 %
Q / Q EPS Net Growth (Q1 MRQ) - - 213.02 % 10.4 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - -72.24 % 67.13 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - - 365.12 % -1.94 %
EPS Net 5 Year Avg. Change - 0.15 % 2.63 % 8.91 %



Aratana Therapeutics reported bottom-line of $ -0.14 in the first quarter, compare to $ -0.19 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 60.99%, while Healthcare sector increased by 22.6%, and overall market improved by 0.3%.

The bottom-line grew by 50.02% from the fourth quarter. Average yearly income per share growth for Aratana Therapeutics is 210.35%, while S & P 500's average annual income per share increase is 8.91% over the five years, including only Businesses with the first quarter 2019 earnings reports.

PETX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) - -11.85 % -17.71 % -53.82 %
Sequential Free Cash Flow Change (Q1 MRQ) - -55.86 % -50.66 % -70.32 %
Y / Y Free Cash Flow Change (Q1 TTM) - 1.47 % -2.09 % 6.94 %
Sequential Free Cash Flow Change (Q1 TTM) - -1.2 % -1.33 % -8.69 %
Free Cash Flow 5 Year Avg. Change - 10.79 % 9.24 % 32.11 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - - - -
Sequential Net Cash Flow Change (Q1 MRQ) - - - -
Y / Y Net Cash Flow Change (Q1 TTM) - - 277.97 % -
Sequential Net Cash Flow Change (Q1 TTM) - - - -
Net Cash Flow 5 Year Avg. Change - 116.02 % 59.89 % -

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) - 10.14 % 21.75 % 3.3 %
Sequential Capital Expenditures Change (Q1 MRQ) - -35.74 % -38.28 % -24.48 %
Y / Y Capital Expenditures Change (Q1 TTM) - 16.49 % 14.07 % 9.51 %
Sequential Capital Expenditures Change (Q1 TTM) - 1.91 % 0.8 % -1.2 %
Capital Expenditures 5 Year Avg. Change - 7.86 % 7.59 % -17.93 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.